|
|
Post by Johan on Nov 4, 2024 22:36:02 GMT -4
|
|
|
|
Post by Johan on Nov 4, 2024 22:37:22 GMT -4
|
|
|
|
Post by Johan on Nov 4, 2024 22:57:49 GMT -4
Itraconazole in Refractory Ovarian Cancer A study explored the use of itraconazole in combination with chemotherapy in patients with refractory ovarian cancer. The study involved 55 patients divided into two groups: 19 received itraconazole with chemotherapy, while 36 received chemotherapy alone. Results showed that patients treated with itraconazole had significantly improved progression-free survival (PFS) of 103 days compared to 53 days in the control group, and overall survival (OS) was 642 days versus 139 days, respectively. Itraconazole likely exerts these effects by inhibiting P-glycoprotein, a protein associated with drug resistance, and reducing angiogenesis. These findings suggest that itraconazole could be a valuable adjunct therapy in the management of platinum-resistant ovarian cancer. Tsubamoto, Hiroshi & Sonoda, Takashi & Yamasaki, Masaaki & Inoue, Kayo. (2014). Impact of Combination Chemotherapy with Itraconazole on Survival of Patients with Refractory Ovarian Cancer. Anticancer research. 34. 2481-7. ------------------------------ anticancersynergies.com/ |
|
